Cetya has a portfolio of over 30 analogs of largazole for evaluation in a multitude of therapeutic indications. The largazole scaffold also lends itself to further modification to develop optimized analogs suited to a particular clinical indication.
GOAL OF THE FORUM
The goal of the Midwest Drug Development conference is to provide industry and investors a single event to learn about cutting edge Midwestern therapeutic technologies and start-up companies.
COVERAGE
The 2018 MWDD conference will offer feature technologies from most major Midwestern universities, including Nebraska and the Nebraska Medical Center, Kansas, Kansas State, Iowa, Iowa State, Illinois, Indiana, Purdue, Washington University, and Colorado State.
TARGETED NETWORK
Ample spaces dedicated to networking will be available for university, industry and investor guests who want to engage in one-on-one partnering discussions regarding their technologies.
Don't miss this unique opportunity!
See the best of the Midwest in one spot
Featured technologies & Speakers
List is tentative, and subject to change at any time.
“Undruggable” dimerization domain of survivin targeted for anticancer drugs
Survivin is an ideal target for discovery of anticancer drugs because it is expressed only in cancers but not adult human tissues.
Antibiotic gel formulation for root canal pathogens
Antibiotic gel formulations, including low concentrations of two antibiotics, are capable of killing root canal pathogens without harming the stem cells inside the root canal.
Broad spectrum anti-viral therapeutics targeting sphingosine-1 phosphate metabolizing enzymes
Sphingosine 1-phospate metabolizing enzymes are involved in modulating cellular responses to a variety of viruses in human and veterinary applications.
CCL21 nanoparticles for cancer immunotherapy
Harness the power of the immune system to recruit immune cells to help treat cancer.
Endocannabinoid derivatives as novel anti-inflammatory and anti-pain drugs
Stable derivatives of naturally occurring endocannabinoid epoxides that produce some of the same medicinal qualities as marijuana
Fatty acid uptake inhibitors as targets for obesity therapy
A proprietary high-throughput screening method to identify and characterize in-cell based assays compounds that inhibit FATP2 mediated fatty acid uptake.
Gastric pH control for the treatment of acid-related disorders
Combination of Proton Pump Inhibitors (PPIs) Omeprazole and Lansoprazole in a buffered composition for 24-hour gastric pH control to treat a variety of acid-related disorders such as Barrett’s Esophagus, Gastroesophageal Reflux Disease, and others.
GLUT Inhibitors for treatment of non-alcoholic fatty liver disease
This transformative initiative focuses on the development and clinical introduction of a first-in-class drug to safely and effectively treat early stage fatty liver disease.
Histone deacetylase inhibitors
Hsp90β selective inhibitors for cancer
Highly selective Hsp90β inhibitors can be developed for the treatment of a variety of diseases that result from increased Hsp90 expression.
Immune stimulating peptides
A unique and patented means to safely and effectively awaken the body’s own natural immune defenses without inflammatory side-effects.
Improving women’s health with designer estrogens
Novel estrogens that retain beneficial effects in metabolic tissues without further risks to reproductive tissues
Long acting antiretroviral therapy
New delivery method opens powerful option for HIV treatment
Low-dose therapeutic for polycystic kidney disease
Pioglitazone, currently approved for treatment of diabetes under the trade name Actos, is effective in delaying cyst growth in polycystic kidney disease (PKD).
Method for producing drug nanocrystals
A scaling-up method for producing drug nanocrystals that combines the top-down and bottom-up approaches.
Mobilization of HIV from lymphatic reservoirs
T cell interactions with specific receptors/ligands on lymphatic endothelium are necessary for the egress of T cells from peripheral lymph nodes into the circulation.
Nano-particulate drug delivery system targeting MM cells through the surface marker CD38
More details coming soon!
Neuroprotection by mitochondria-targeted Metformin
Metformin, a naturally-occurring biguanide, is an FDA-approved high-safety profile diabetes drug that has been used extensively for decades.
Next-gen anticancer drugs based on natural compounds
InnoBioPharma has developed several novel drug candidates (two in pre-clinical trials) that are particularly effective against aggressive cancers that lack effective drug therapy.
NF-κB pathway inhibitors
A molecule capable of specifically inhibiting the NF-κB pathway, a key target involved in a variety of cancers and other diseases.
Non-opioid for treating chronic pain and opioid dependence
An effective method of treatment for chronic and inflammatory pain by inhibiting selective adenylyl cyclases, especially adenylyl cyclase 1. Compounds may also prevent and/or reduce opioid dependence.
Novel anthelmintic drugs
Novel assay and peptide inhibition of calpain-5 enzyme
Peptide-based therapeutic agents that inhibit the CAPN5 enzyme.
Novel broad-spectrum antivirals against noroviruses, picornaviruses and coronaviruses
Novel inhibitors targeting 3C or 3CL virus proteases.
Novel cancer immune-based therapy
Cancers persist only when they evade the host’s immune system. This novel cancer therapy resensitizes the host immune system to cancer epitopes through a novel method involving vaccination with a treated sample of the biopsied tumor. Trials in canines have demonstrated efficacy. Patents pending.
Novel compounds for angiogenesis-mediated diseases
Wet age-related macular degeneration (AMD) is known to negatively affect aging populations. The disease can result in blindness and can lead to a severe decline in quality of life.
Novel delivery platform for small molecules, gene therapy agents and others
A substrate mediated delivery system for highly controlled local and sustained release of any hydrophobic or hydrophilic cargo.
Novel kappa opioid-selective ligands for neurological disorders
More info coming soon!
Novel peptides for therapeutic treatment of injury related to ischemia/reperfusion
Therapeutic peptides to combat excessive inflammation and tissue damage in response to ischemia/reperfusion (IR).
POSH inhibitor-based cancer therapy
Cell-specific non-toxic reagent for the treatment of hematological and other cancers. Data using micelles composed of peptide amphiphiles targeted using aptamers demonstrate efficacy against a wide range of human and canine cancers, as well as low toxicity in vivo, and 2-3x longer median survival. Patents issued and pending.
Prostate cancer vaccine
A therapeutic vaccine for patients with recurrent prostate cancer that effectively destroys expressing tumor cells while leaving normal cells unharmed.
Protease inhibitor drugs with improved PK, bioavailability
A collaboration between Kansas State University and Wichita State University has led to the development of protease inhibitors with improved pharmacokinetics (PK) and bioavailability using a prodrug approach of peptidyl aldehyde compounds.
Small molecule regulators of mitochondrial fusion and methods of use
More info coming soon!
SMN2 catalytic core for spinal muscular atrophy treatment
In humans, there are two nearly identical copies of the Survival Motor Neuron (SMN) gene, SMN1 and SMN2. Loss of SMN1 in conjunction with skipping of SMN2 exon 7 in pre-mRNA splicing—which results in a truncated, unstable SMN—leads to spinal muscular atrophy.
Splicing correction in spinal muscular atrophy
Targeting disease-causing DNA, RNA
This talk will focus on the design, synthesis, and study of ligands that target DNA and RNA repeat sequences that cause disease.
Therapy for the reversal of Type I Diabetes
Combination treatment of Ig-GAD2 and stem cells to cure Type I Diabetes (TID). Data demonstrate a functional cure in a mouse model for TID through restoration of immune tolerance coupled with regeneration of endothelial cells in the pancreatic islets. Patents issued and pending.
Top1/TDP1/TDP2 Triple inhibitor anticancer agents
Azaindenoisoquinoline compounds that act as inhibitors of Top1, TDP1, and TDP2 for cancer treatment
TR3 biologics for the treatment of cancer
TR3 Technology delivers a new generation of TNF superfamily TRAIL (TNF-related apoptosis-inducing ligand, designated TR3) directly to MUC16-expressing cancer cells.
Tumor-targeted chemerin fusion protein
More info coming soon!
UGDH as a novel target for castration-resistant prostate cancer
Prostate Cancer (PC) is commonly treated with androgen deprivation therapy (ADT), but tumors may become resistant to androgen removal and are then categorized as Castration-Resistant PC (CRPC).
Unique LKB1-AMPK activator for polycystic kidney disease
A novel compound and method for treating Polycystic Kidney Disease utilizing a novel liver kinase B1 activator
Unlock the potential of photodynamic/ultraviolet light therapy
LoDos Theranostics has developed “first-in-class” nanoparticles called “Radio-Luminescent Nano Particles (RLNPs)” which will be injected into the tumor before a patient receives radiation treatment: The first product to endogenously deliver UV light to deep tumors.
Water soluble glucagon derivative stable at neutral pH
A method of stabilizing glucagon and improving its solubility in aqueous form.
Conference Schedule
Number of participants is limited!
Don't miss your chance. Find the next big thing in Omaha
Latest News
It’s last call for presentations at the Midwest Drug Development conference, officials announced today.
Only 10 slots remain open in the two-day slate of early- and mid-stage technologies that will be presented to guests from the worlds of biomedical therapeutics and investor groups.
The MidWest Drug Development Conference is now accepting registrations to attend a two-day event focused on highlighting the best early- and mid-stage therapeutic technologies that Midwestern universities have to offer.
The Midwest Drug Development Conference, a new biomedical partnering event, will come to Omaha next year, officials at the University of Nebraska Medical Center and its technology transfer and commercialization office, UNeMed, announced today.
Venue & Contacts
Hotel website: http://www.downtownomahamarriott.com/
Contacts
Event Coordinators
Matt BoehmIndustry & University Liason
mboehm@unmc.edu | 402-559-2468
Michael DixonSponsors & Donors
mdixon@unmc.edu | 402-559-2468
Send us a message
Our Sponsors and Partners
Sponsorship Packages
Platinum Sponsor
- Named sponsor for one lunch
Gold Sponsor
- Named sponsor for one Breakfast
Silver Sponsor
- One Category 3 item included